1 Psychiatric and Nervous Drugs Market Overview
1.1 Product Overview and Scope of Psychiatric and Nervous Drugs
1.2 Psychiatric and Nervous Drugs Segment by Type
1.2.1 Global Psychiatric and Nervous Drugs Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Antidepressants
1.2.3 Anti-anxiety
1.2.4 Antipsychotic
1.2.5 Mood Stabilizing
1.2.6 Stimulant Medications
1.2.7 Others
1.3 Psychiatric and Nervous Drugs Segment by Application
1.3.1 Global Psychiatric and Nervous Drugs Sales Comparison by Application: (2022-2028)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Psychiatric and Nervous Drugs Market Size Estimates and Forecasts
1.4.1 Global Psychiatric and Nervous Drugs Revenue 2017-2028
1.4.2 Global Psychiatric and Nervous Drugs Sales 2017-2028
1.4.3 Psychiatric and Nervous Drugs Market Size by Region: 2017 Versus 2021 Versus 2028
2 Psychiatric and Nervous Drugs Market Competition by Manufacturers
2.1 Global Psychiatric and Nervous Drugs Sales Market Share by Manufacturers (2017-2022)
2.2 Global Psychiatric and Nervous Drugs Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Psychiatric and Nervous Drugs Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Psychiatric and Nervous Drugs Manufacturing Sites, Area Served, Product Type
2.5 Psychiatric and Nervous Drugs Market Competitive Situation and Trends
2.5.1 Psychiatric and Nervous Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Psychiatric and Nervous Drugs Players Market Share by Revenue
2.5.3 Global Psychiatric and Nervous Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Psychiatric and Nervous Drugs Retrospective Market Scenario by Region
3.1 Global Psychiatric and Nervous Drugs Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Psychiatric and Nervous Drugs Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.3.1 North America Psychiatric and Nervous Drugs Sales by Country
3.3.2 North America Psychiatric and Nervous Drugs Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.4.1 Europe Psychiatric and Nervous Drugs Sales by Country
3.4.2 Europe Psychiatric and Nervous Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Psychiatric and Nervous Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Psychiatric and Nervous Drugs Sales by Region
3.5.2 Asia Pacific Psychiatric and Nervous Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.6.1 Latin America Psychiatric and Nervous Drugs Sales by Country
3.6.2 Latin America Psychiatric and Nervous Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.6.6 Colombia
3.7 Middle East and Africa Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Psychiatric and Nervous Drugs Sales by Country
3.7.2 Middle East and Africa Psychiatric and Nervous Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Psychiatric and Nervous Drugs Historic Market Analysis by Type
4.1 Global Psychiatric and Nervous Drugs Sales Market Share by Type (2017-2022)
4.2 Global Psychiatric and Nervous Drugs Revenue Market Share by Type (2017-2022)
4.3 Global Psychiatric and Nervous Drugs Price by Type (2017-2022)
5 Global Psychiatric and Nervous Drugs Historic Market Analysis by Application
5.1 Global Psychiatric and Nervous Drugs Sales Market Share by Application (2017-2022)
5.2 Global Psychiatric and Nervous Drugs Revenue Market Share by Application (2017-2022)
5.3 Global Psychiatric and Nervous Drugs Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Pfizer Psychiatric and Nervous Drugs Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Ely Lilly
6.2.1 Ely Lilly Corporation Information
6.2.2 Ely Lilly Description and Business Overview
6.2.3 Ely Lilly Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Ely Lilly Psychiatric and Nervous Drugs Product Portfolio
6.2.5 Ely Lilly Recent Developments/Updates
6.3 Actavis
6.3.1 Actavis Corporation Information
6.3.2 Actavis Description and Business Overview
6.3.3 Actavis Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Actavis Psychiatric and Nervous Drugs Product Portfolio
6.3.5 Actavis Recent Developments/Updates
6.4 Mylan
6.4.1 Mylan Corporation Information
6.4.2 Mylan Description and Business Overview
6.4.3 Mylan Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Mylan Psychiatric and Nervous Drugs Product Portfolio
6.4.5 Mylan Recent Developments/Updates
6.5 Randox
6.5.1 Randox Corporation Information
6.5.2 Randox Description and Business Overview
6.5.3 Randox Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Randox Psychiatric and Nervous Drugs Product Portfolio
6.5.5 Randox Recent Developments/Updates
6.6 Intellipharmaceutics
6.6.1 Intellipharmaceutics Corporation Information
6.6.2 Intellipharmaceutics Description and Business Overview
6.6.3 Intellipharmaceutics Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Intellipharmaceutics Psychiatric and Nervous Drugs Product Portfolio
6.6.5 Intellipharmaceutics Recent Developments/Updates
6.7 Astrazeneca
6.6.1 Astrazeneca Corporation Information
6.6.2 Astrazeneca Description and Business Overview
6.6.3 Astrazeneca Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Astrazeneca Psychiatric and Nervous Drugs Product Portfolio
6.7.5 Astrazeneca Recent Developments/Updates
6.8 Lundbeck
6.8.1 Lundbeck Corporation Information
6.8.2 Lundbeck Description and Business Overview
6.8.3 Lundbeck Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Lundbeck Psychiatric and Nervous Drugs Product Portfolio
6.8.5 Lundbeck Recent Developments/Updates
6.9 Allergan
6.9.1 Allergan Corporation Information
6.9.2 Allergan Description and Business Overview
6.9.3 Allergan Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Allergan Psychiatric and Nervous Drugs Product Portfolio
6.9.5 Allergan Recent Developments/Updates
6.10 GSK
6.10.1 GSK Corporation Information
6.10.2 GSK Description and Business Overview
6.10.3 GSK Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
6.10.4 GSK Psychiatric and Nervous Drugs Product Portfolio
6.10.5 GSK Recent Developments/Updates
6.11 Otsuka Pharmaceutical
6.11.1 Otsuka Pharmaceutical Corporation Information
6.11.2 Otsuka Pharmaceutical Psychiatric and Nervous Drugs Description and Business Overview
6.11.3 Otsuka Pharmaceutical Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Otsuka Pharmaceutical Psychiatric and Nervous Drugs Product Portfolio
6.11.5 Otsuka Pharmaceutical Recent Developments/Updates
6.12 Takeda
6.12.1 Takeda Corporation Information
6.12.2 Takeda Psychiatric and Nervous Drugs Description and Business Overview
6.12.3 Takeda Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Takeda Psychiatric and Nervous Drugs Product Portfolio
6.12.5 Takeda Recent Developments/Updates
6.13 NHU Group
6.13.1 NHU Group Corporation Information
6.13.2 NHU Group Psychiatric and Nervous Drugs Description and Business Overview
6.13.3 NHU Group Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
6.13.4 NHU Group Psychiatric and Nervous Drugs Product Portfolio
6.13.5 NHU Group Recent Developments/Updates
6.14 Shionogi
6.14.1 Shionogi Corporation Information
6.14.2 Shionogi Psychiatric and Nervous Drugs Description and Business Overview
6.14.3 Shionogi Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Shionogi Psychiatric and Nervous Drugs Product Portfolio
6.14.5 Shionogi Recent Developments/Updates
6.15 APOTEX
6.15.1 APOTEX Corporation Information
6.15.2 APOTEX Psychiatric and Nervous Drugs Description and Business Overview
6.15.3 APOTEX Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
6.15.4 APOTEX Psychiatric and Nervous Drugs Product Portfolio
6.15.5 APOTEX Recent Developments/Updates
6.16 Chengdu Kanghong Pharmaceutical
6.16.1 Chengdu Kanghong Pharmaceutical Corporation Information
6.16.2 Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Description and Business Overview
6.16.3 Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Product Portfolio
6.16.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
6.17 HUAHAI
6.17.1 HUAHAI Corporation Information
6.17.2 HUAHAI Psychiatric and Nervous Drugs Description and Business Overview
6.17.3 HUAHAI Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
6.17.4 HUAHAI Psychiatric and Nervous Drugs Product Portfolio
6.17.5 HUAHAI Recent Developments/Updates
6.18 Zhejiang Jianfeng
6.18.1 Zhejiang Jianfeng Corporation Information
6.18.2 Zhejiang Jianfeng Psychiatric and Nervous Drugs Description and Business Overview
6.18.3 Zhejiang Jianfeng Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
6.18.4 Zhejiang Jianfeng Psychiatric and Nervous Drugs Product Portfolio
6.18.5 Zhejiang Jianfeng Recent Developments/Updates
6.19 Beijing Winsunny Pharmaceutical
6.19.1 Beijing Winsunny Pharmaceutical Corporation Information
6.19.2 Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Description and Business Overview
6.19.3 Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
6.19.4 Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Product Portfolio
6.19.5 Beijing Winsunny Pharmaceutical Recent Developments/Updates
7 Psychiatric and Nervous Drugs Manufacturing Cost Analysis
7.1 Psychiatric and Nervous Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Psychiatric and Nervous Drugs
7.4 Psychiatric and Nervous Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Psychiatric and Nervous Drugs Distributors List
8.3 Psychiatric and Nervous Drugs Customers
9 Psychiatric and Nervous Drugs Market Dynamics
9.1 Psychiatric and Nervous Drugs Industry Trends
9.2 Psychiatric and Nervous Drugs Market Drivers
9.3 Psychiatric and Nervous Drugs Market Challenges
9.4 Psychiatric and Nervous Drugs Market Restraints
10 Global Market Forecast
10.1 Psychiatric and Nervous Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Psychiatric and Nervous Drugs by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Psychiatric and Nervous Drugs by Type (2023-2028)
10.2 Psychiatric and Nervous Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Psychiatric and Nervous Drugs by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Psychiatric and Nervous Drugs by Application (2023-2028)
10.3 Psychiatric and Nervous Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Psychiatric and Nervous Drugs by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Psychiatric and Nervous Drugs by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
